sciencemag.org
72%
965
Could a rare clotting disorder dash the world's hopes for AstraZeneca's COVID-19 vaccine?
Kai Kupferschmidt, Gretchen VogelScience’s COVID-19 reporting is supported by the Heising-Simons Foundation.In the tumultuous rollout of AstraZeneca's COVID-19 vaccine, all eyes were on the United States this week, where the company had a highly public communication breakdown over the vaccine's efficacy with an expert panel overseeing a large study in the Americas.